---
document_datetime: 2025-12-09 09:07:53
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/kostaive-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: kostaive-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.7047499
conversion_datetime: 2025-12-15 02:27:04.762794
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## Kostaive

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number                    | Scope                                                                                                                  | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|---------------------------------------|------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type II / EMA/VR/0000271850 | C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.13 Other variations not specifically covered elsewhere in this Annex | 23/10/2025                          |                                             | SmPC and PL                      |           |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                                       | which involve the submission of studies to the competent authority - Accepted Update of section 4.8 of the SmPC in order to add Neutrophil count decreased to the list of adverse drug reactions (ADRs) with frequency 'not known' based on the final report from study ARCT-165-01 (NCT05037097) listed as a category 3 study in the RMP. This is a phase 1/2 randomized, observer-blind study of the safety, reactogenicity, and immunogenicity of 3 SARS-CoV-2 RNA vaccine candidates in adults previously vaccinated and not previously vaccinated against SARS-CoV-2. The Package Leaflet is updated accordingly.   |            |     |             |                                                                                                                                                                                                                            |
|---------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IB / EMA/VR/0000281497 | B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.z Other changes - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                           | 30/07/2025 | N/A |             |                                                                                                                                                                                                                            |
| Variation type II / EMA/VR/0000269728 | C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data - Accepted                                                                                                                                                                                                                                                                                                                                                                                                     | 24/07/2025 |     | SmPC and PL | SmPC section 5.1. is updated to add data for immune response against SARS-CoV-2 ancestral strain and Omicron BA.4/5 variant up to 12 months. For more information, please refer to the Summary of Product Characteristics. |

<div style=\"page-break-after: always\"></div>

|                                                         | Update of section 5.1 of the SmPC in order to include data based on the final results from study ARCT-154-J01 (jRCT2071220080). This is a Phase 3, randomised, observer-blind, active- controlled, comparative study conducted in Japan to evaluate the safety and immunogenicity of a single dose of ARCT- 154 (ancestral strain) administered intramuscularly to participants aged 18 years or older. In addition, the MAH took the opportunity bring the PI in line with the latest QRD template version 10.4.   |            |            |                        |
|---------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|
| Marketing Authorisation Transfer - H / EMA/T/0000257405 | - Transfer of a marketing authorisation - transfer of marketing authorisation from Arcturus Therapeutics Europe B.V. to Seqirus Netherlands B.V.                                                                                                                                                                                                                                                                                                                                                                    | 20/03/2025 | 16/04/2025 | SmPC, Labelling and PL |